Velorum Therapeutics Revolutionizes Cancer Treatment with Enhanced Efficacy

Velorum Therapeutics is advancing a novel class of cancer drugs designed to disrupt tumor metabolism, effectively starving cancer cells. By targeting heme, a molecule essential for cancer growth, their patented drugs aim to deprive cancer cells of vital nutrients, paving the way for promising human clinical trials, starting with lung cancer, next year.
Their research has demonstrated in animal models that our drugs exhibit high efficacy against multiple cancers, while sparing healthy cells even at maximum doses. Additionally, by depriving tumors of essential nutrients, they render them more vulnerable to existing cancer therapies such as radiation, chemotherapy, and immunotherapies.